Passage Bio Inc. is a biotechnology company focused on the development of transformative therapies for rare monogenic central nervous system (CNS) diseases. The primary aim of Passage Bio is to harness advanced gene therapy techniques to address unmet medical needs in the CNS area, using innovative approaches to deliver genetic materials precisely to the affected areas in the brain and spinal cord. Their therapeutic pipeline is built upon an exclusive collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in gene therapy research, enabling access to cutting-edge technologies and proprietary capabilities. Passage Bio's research primarily impacts the healthcare sector, specifically the genetic therapy subfield, targeting severe genetic disorders characterized by significant morbidity or mortality. In the financial market, Passage Bio Inc. plays a pivotal role within the biotechnology segment, offering potential advancements that could shape future treatments and improve patient outcomes. As it navigates the dynamic landscape of biotechnology, Passage Bio continues to push the boundaries of medical science with the goal of developing life-changing treatments for patients with rare neurological conditions.